SEARCH:      Monitor Keywords |  Custom RSS

Organic compounds -- part of the class 532-570 series June invention type 06/10

20100160616 - Novel process for the extraction of furostanolic saponins from fenugreek seeds: A novel, commercially viable process for the extraction of high purity (>70%), bioactive furostanolic saponins including protodioscin (>30%), from the seeds of fenugreek (Trigonella foenumgraecum) comprising essentially the steps of powdering of the natural material followed by a first extraction, an ion-exchange chromatographic purification and a second extraction using a... Agent: Jerome D. Jackson (jackson Patent Law Office)

20100160618 - Expanding the eukaryotic genetic code: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic... Agent: Quine Intellectual Property Law Group, P.C.

20100160617 - Nuclease-resistant rna aptamer inhibiting replication of hepatitis c virus replicon: Disclosed a nuclease-resistant RNA aptamer for inhibiting the replication of HCV replicon. This aptamer is capable of binding specifically to HCV NS5B and inhibiting the proliferation of the HCV replicon, and is composed of at least one sequence selected from a group consisting of SEQ ID NOS. 1 to 4,... Agent: Lowe Hauptman Ham & Berner, LLP

20100160619 - Compositions and methods for using a solid support to purify dna: Reagents, methods and kits for the purification of DNA from biological materials are provided.... Agent: Seed Intellectual Property Law Group PLLC

20100160620 - N-pyrazole a2a receptor agonists: a

20100160621 - Synthesis of alkoxylated sucrose esters: forming an initial reaction mixture of a sucrose ester and from about 0.01% to about 5% of a catalyst; and forming an initial reaction product by reacting the initial reaction mixture with an epoxide for a period of time in the range of from about 30 minutes to about 6... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100160622 - Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide: The present invention provides improved methods for producing a solution containing high molecular weight isolated Streptococcus pneumoniae capsular polysaccharides having phosphodiester linkages between saccharide repeat units. In certain methods, CO2 is supplied to a fermentation culture of Streptococcus pneumoniae bacterial cells that produce capsular polysaccharide serotypes containing phosphodiester linkages between... Agent: Wyeth LLC Patent Law Group

20100160623 - Cyclodextrin inclusion complexes and methods of preparing same: The present invention provides a product comprising a guest complexed with a cyclodextrin wherein the guest is more stable in the product and does not degrade as quickly as a product comprising the same guest without a cyclodextrin. In addition, the present invention provides a method of stabilizing guests with... Agent: Michael Best & Friedrich LLP

20100160624 - Process for producing high-purity sucrose: Improved processes for the purification of raw or refined sugar, or sucrose, to produce sucrose and sucrose-related products having substantially no inorganic impurities are described, wherein the processes include the use of both cation and anion exchange resins. In accordance with the process, a sucrose starting material, such as refined... Agent: Locke Lord Bissell & Liddell LLP Attn:IPDocketing

20100160625 - Novel preparation of 6-o-acyl chlorosucrose from anhydrous cholorinated reaction mass: A process is described for production of a chlorinated sucrose from a process stream containing a 6-O-protected chlorinated sucrose derived from chlorination of 6-O-protected sucrose wherein the process stream is treated under conditions which prevent or reverse deacylation of 6-O-protected chlorinated sucrose, extracting the same in a solvent, washing most... Agent: The Nath Law Group

20100152429 - Sodium salt of disaccharide compound, method for producing the same, and use of the same: Disclosed are a sodium salt represented by the average formula (I) below, and a method for producing such a sodium salt. (In the formula, m1, n1, m2 and n2 independently represent 0 or a positive number not greater than 2, while satisfying m1+n1=2, m2+n2=2, 0<m1+m2<4 and 0<n1+n2<4.) Also disclosed is... Agent: Mccarter & English, LLP Boston

20100152430 - Process for preparing compounds of chitosan saccharified with aminosugar: A process for preparing compounds of chitosan saccharified with aminosugar, adopts chitosan derivatives, aminosugar derivatives and anhydride derivatives as raw materials to synthesize target products. The process comprises: covalently bonding an anhydride derivative as a bonding arm to an aminosugar derivative, so as to form a monosaccharide derivative having an... Agent: Zhen Zheng Lu

20100152431 - Compositions, probes and conjugates and uses thereof: The present invention relates to compositions useful as probes and in other applications and methods of their use. In some embodiments, nucleotides are prepared and functionalized with dyes. In some embodiments a first molecule is functionalized with an alkynyl group, a second molecule is functionalized with an azide group, and... Agent: Casimir Jones, S.c.

20100152432 - Dna sequences and primers for identifying methicillin-resistent staphylococcus aureus mw2 and usa300 strains: The present invention relates to unique agr gene sequences and primer sets for identifying CA-MRSA MW2 or CA-MRSA USA300 strains in clinical samples from various sources. More specifically, this invention provides fluorescent labeled primers which are designed to amplify 1) two unique agr gene sequences from each strain, 2) a... Agent: Lu & Associates, P.C.

20100152433 - Antiviral agent: The main purpose of the present invention is to provide a novel antiviral agent having a useful pharmacological action. The present inventors found that the above-described purpose can be achieved by a complex in which two synthetic RNAs (e.g., poly-I and poly-C) that can together form a double strand are... Agent: Darby & Darby P.C.

20100152434 - Protein kinase-binding nucleosides and associated methods: Therapeutically active nucleosides and associated methods are provided. In one aspect, a nucleoside molecule having a general structural similar to ATP. Such nucleosides have a structure that allows binding to, and subsequent regulation of, protein kinase molecules. As such, the nucleosides of the present invention have may be capable of... Agent: Thorpe North & Western, LLP.

20100152435 - Compositions and processes for the selective catalytic oxidation of alcohols: Processes for oxidation of primary alcohols or aldehydes into the corresponding carboxylic acids are provided herein, including processes for the aerobic catalytic oxidation of a hydroxyl moiety pendant to a cyclic carbohydrate to a carboxylic acid in a manner that preserves the cyclic carbohydrate structure. The oxidation processes may be... Agent: Indianapolis Office 27879 Brinks Hofer Gilson & Lione

20100152436 - Catalyst and process for hydrogenating organic compounds comprising hydrogenatable groups: The invention relates to a shell catalyst containing ruthenium as an active metal, alone or together with at least one other metal of the auxiliary group IB, VIIB or VIII of the periodical system of the elements (CAS version), and applied to a carrier containing silicon dioxide as a carrier... Agent: Connolly Bove Lodge & Hutz LLP

20100145035 - Method of synthesizing macrolide compounds: The present invention relates to methods for synthesizing macrolide compounds which are known to have antibacterial activity, and are useful in the therapy of bacterial infections in mammals. More specifically, the invention relates to methods for synthesizing the macrolide antibiotic, gamithromycin utilizing a novel configuration of catalysts, chemical structures, and/or... Agent: Judy Jarecki-black Ph.d., J.d.

20100145036 - Chemical linkers and cleavable substrates and conjugates thereof: The present disclosure provides drug-ligand conjugates and drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.... Agent: Medarex C/o Darby & Darby P.C.

20100145037 - Dna amplification and sequencing using dna molecules generated by random fragmentation: The present invention is directed to methods to prepare a DNA molecule or a plurality of DNA molecules by random fragmentation. In some embodiments, the present invention regards preparing a template for DNA sequencing by random fragmentation. In specific embodiments, the random fragmentation comprises chemical fragmentation, mechanical fragmentation, or enzymatic... Agent: Fulbright & Jaworski L.L.P.

20100145038 - Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating gene expression using short interfering nucleic acid (siNA) molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA... Agent: Merck C/o Sirna Therapeutics, Inc.

20100145039 - Sirna targeting nucleoporin 62kda (nup62): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20100137569 - Rebaudioside a composition and method for purifying rebaudioside a: Exemplary embodiments of this invention encompass a method for purifying a low purity steviol glycoside composition. In particular, this invention relates to a method for purifying low purity steviol glycoside compositions to obtain substantially pure steviol glycoside compositions comprising approximately 95% or greater steviol glycosides and approximately 75% or greater... Agent: Sutherland Asbill & Brennan LLP

20100137570 - Host cell protein knock-out cells for production of therapeutic proteins: The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100137571 - Dengue serotype 1 attenuated strain: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.... Agent: Stites & Harbison PLLC

20100137572 - Oxidation process: e

20100137573 - Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids: The present invention provides selenium derivatives of nucleosides, nucleoside phosphoramidites, nucleotides, nucleotide triphosphates, oligonucleotides, polynucleotides, and larger nucleic acids and methods for their synthesis. Selenium derivatives of both ribonucleic acids and deoxyribonucleic acids, as well as methods for their synthesis, crystallization and uses in structural determinations, particularly by X-ray crystallographic... Agent: Sutherland Asbill & Brennan LLP

20100137574 - System and method for the automated extraction of nucleic acids: A system and method for the automated extraction of nucleic acids from nucleic acids containing samples are disclosed. In the system, reagents provided in cavities of a reagent plate are transferred to samples accommodated in a process plate using a pipetting device comprising pipettes provided with disposable pipette tips for... Agent: Dinsmore & Shohl, LLP Fifth Third Center

20100137575 - Universal biological sample processing: A method for preparing a sample by utilizing a mechanical force in the presence of a size stabilizer to break apart the sample to obtain nucleic acid molecules in a usable size range.... Agent: Hiscock & Barclay, LLP

20100137576 - 5' o [(n acyl)amidophosphate] and 5' o [(n acyl)amidothiophosphate] and 5' o [(n acyl)amidodithiophosphate] and 5' o [(n acyl)amidoselenophosphate] derivatives of nucleosides and processes for the manufacture thereof: The subject of the invention includes 5′-O-[(N-acyl)amidophosphate]- and 5′-O-[(N-acyl)amidothiophosphate]- and 5′-O-[(N-acyl)amidodithiophosphate]- and 5′-O-[(N-acyl)amidoselenophosphate]- derivatives of nucleosides.... Agent: Brooks Kushman P.C.

20100137577 - Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient: Disclosed are adenosine derivatives, methods for the synthesis thereof, and pharmaceutical compositions for the prevention and treatment of inflammatory diseases, comprising the same as an active ingredient. The adenosine derivatives have high binding affinity and selectivity for adenosine receptors, especially for A3 adenosine receptors and act as A3 adenosine receptor... Agent: Fm Therapeutics/nih/bstz

20100137578 - Cellulose ester film for optical use, and polarizing plate and liquid crystal display using such cellulose ester film for optical use: Disclosed is a cellulose ester film for optical use which contains an ultraviolet absorbent and hardly suffers from retardation fluctuations. The cellulose ester film is excellent in spectral absorption property as an optical film. In addition, the cellulose ester film is free from coloration and has excellent transparency, which having... Agent: Lucas & Mercanti, LLP

20100137579 - Process for purifying medical grade hyaluronic acid: A process for purifying medical grade hyaluronic acid from a biological source under continual changed pH value is disclosed.... Agent: Wpat, PC Intellectual Property Attorneys